bioMerieux (OTCMKTS:BMXMF) Shares Climb 8.3% – Still a Buy?

bioMerieux (OTCMKTS:BMXMF)’s stock price was up 8.3% during trading on Tuesday. The company traded as high as $95.00 and last traded at $95.00. 105 shares changed hands during mid-day trading, a decline of 71% from the average session volume of 363 shares. The stock had previously closed at $87.75.

Analyst Upgrades and Downgrades

Several analysts have weighed in on BMXMF shares. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of bioMerieux in a research note on Wednesday, June 17th. Zacks Research upgraded shares of bioMerieux from a “strong sell” rating to a “hold” rating in a research note on Monday, September 28th. Finally, Morgan Stanley reiterated an “underweight” rating on shares of bioMerieux in a research note on Friday, September 11th. Five analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Reduce”.

bioMerieux Stock Up 4.0%

The firm’s 50-day moving average is $84.46 and its two-hundred day moving average is $86.19.

About bioMerieux

bioMérieux is a France-based healthcare company specializing in in vitro diagnostics. The company develops, manufactures and markets diagnostic systems, reagents and software used to detect infectious diseases, support antimicrobial therapy decisions and assist with disease management.

Its product portfolio includes solutions for microbiology, molecular biology, immunoassays and syndromic testing. bioMérieux’s systems are used by hospitals, clinical laboratories and healthcare providers, while its industrial applications serve the food, pharmaceutical and cosmetics industries by helping customers monitor contamination, quality and safety.

Founded in 1963 by Alain Mérieux, bioMérieux traces its heritage to the Mérieux family’s work in medical diagnostics.